Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Gain Therapeutics a consensus recommendation of "Moderate Buy" (four buys, one sell) with an average 12‑month target price of $8.50.
• Marshall Wace LLP sharply increased its stake (up 849% to 1.66M shares, ~$5.35M) and other institutions added positions, leaving institutional ownership at about 11.97%.
• Shares trade cheaply versus targets — opened at $1.80 with a market cap of $76M and a 52‑week range of $1.41–$4.34 — and the company reported Q1 EPS of ($0.11), beating estimates.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.50.

Several brokerages have recently issued reports on GANX. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Gain Therapeutics in a research note on Monday, December 29th. Finally, Roth Mkm reaffirmed a "buy" rating and set a $10.00 price target on shares of Gain Therapeutics in a research note on Friday, December 19th.

Hedge Funds Weigh In On Gain Therapeutics

Several large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at $45,000. Engineers Gate Manager LP acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at $47,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at $120,000. Marshall Wace LLP lifted its stake in shares of Gain Therapeutics by 849.3% during the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company's stock valued at $5,353,000 after acquiring an additional 1,487,186 shares during the period. Finally, State Street Corp lifted its stake in shares of Gain Therapeutics by 72.9% during the fourth quarter. State Street Corp now owns 157,537 shares of the company's stock valued at $507,000 after acquiring an additional 66,400 shares during the period. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Price Performance

Shares of GANX stock opened at $1.80 on Friday. The stock's fifty day moving average is $2.11 and its 200-day moving average is $2.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.63 and a current ratio of 6.63. The stock has a market capitalization of $76.03 million, a PE ratio of -2.95 and a beta of 0.11. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Thursday, March 26th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. Equities research analysts expect that Gain Therapeutics will post -1 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.